Cryoport completes CRYOPDP divestiture to DHL for ~$200M in cash; launches strategic partnership

Cryoport, Inc.

Total cash consideration of ~$200M: $133M purchase price plus repayment of $77.2M in intercompany loans.
Strategic partnership with DHL Group to collaborate on life sciences supply chain, expanding APAC and EMEA reach.
Pro forma net loss from continuing ops improves: Q1 2025 loss $7.3M vs. $9.0M reported; FY2024 loss $104.5M vs. $114.8M.
Company says deal provides capital to focus on advancing Life Science Services platform and Regenerative Medicine market.
Divested entity represented $71.6M revenue in FY2024; proceeds bolster cash to $246.3M pro forma as of March 31, 2025.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.